Category Archives: Stem Cell Research

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 18 hours ago This image shows a hES cell colony immunostained for pluripotency markers nanog (red) and TRA-1-60 (green). Credit: Dusko Ilic, King's College London Scientists from King's College London have announced that 16 human embryonic stem (hES) cell lines have been approved by the US National Institutes of Health (NIH) and placed on their Stem Cell Registry, making them freely available for federally-funded research in the USA. The stem cell lines, which carry genes for a variety of hereditary disorders such as Huntington's disease, spinal muscular dystrophy and cystic fibrosis, are considered to be ideal research tools for designing models to understand disease progression, and ultimately in helping scientists develop new treatments for patients. King's is now one of the five biggest providers of disease-specific human embryonic stem cells lines on the NIH Registry, and the largest from the UK. The development is a significant milestone for King's and keeps the university at the forefront of global research into regenerative medicine. Embryonic stem cell lines are grown from frozen embryos donated by … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/qx5lqb/single_cell) has announced the addition of the "Single Cell Genomics (SCG) Report 2013: Market Size, Segmentation, Growth, Competition and Trends" report to their offering. Single cell genomics (SCG) is a fast growing, emerging approach in which genomic technologies (i.e., that assess nucleic acids such as DNA or RNA) are applied at the level of single cells, rather than at the level of an entire cell population. The first edition of this report reviews the market size, segmentation, growth and trends of the SCG market. We assess the SCG market across 7 segments and 32 sub-segments: - Customer (academia, biopharma, applied markets, clinical) - Workflow step (cell isolation, sample preparation, genomic analysis) - Analytical technology (PCR, qPCR, microarray, next-generation-sequencing, other) - Field-of-study (oncology, basic cell biology, stem cell biology, microbiology, neurology, immunology, other) - Application (genomic variation, subpopulation characterization, circulating tumor cells, cell differentiation / reprogramming, method, other) - Product type (instruments, reagents) See more here: Research and Markets: Single Cell Genomics (SCG) Report 2013: Market Size, Segmentation, Growth, Competition and Trends … Continue reading →

Duchenne Muscular Dystrophy and Stem Cell Research - Helen Blau, Stanford Medicine Go to: http://www.cirm.ca.gov/our-progress for more info on our progress to help accelerate stem cell therapies. Duchenne muscular dystrophy (DMD) is the mos... By: California Institute for Regenerative Medicine … Continue reading →

EYSINS, Switzerland, September 23, 2013 /PRNewswire/ -- Biosafe is pleased to announce that, in partnership with its Indian Distributor Span Healthcare Private Ltd., it has achieved major expansion of its stem cell banking business in India, winning major new customer deals consecutively. In the public stem cell banking area, Jeevan Blood Bank and Research Centre in Chennai is expanding its program and will process its full volume of stem cell samples with Biosafe's proprietary Sepax cell separation system and Coolmix cryo-preparation cooling and mixing device. On the family banking side, the renowned companies Cordlife India and Cryobanks International are likewise moving to automated processing exclusively by Sepax. Such expansion is a milestone as the majority of cord blood samples in India will now be processed with Biosafe technology. Olivier Waridel, CEO of the Biosafe Group, commented: "These recent wins illustrate the potential of Biosafe's Sepax technology in the BRIC economies. Biosafe demonstrates its ability to meet customer expectations through its vast portfolio of processing solutions and is committed to further support stem cell banking expansion in India together with Span Healthcare". About the Biosafe Group Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of … Continue reading →

HARVARD University has launched a $US6.5 billion ($A6.92 billion) capital campaign that, if successful, would be the largest fundraising effort in the history of higher education. The school on Saturday said the campaign had broad goals spanning all its schools and would fund research into neuroscience, stem cell science and low-cost energy for the developing world. The campaign will target major renovations of the university's undergraduate housing and increase its study of new learning and teaching strategies. It also aims to expand the school's global presence, including through an ongoing project to develop a centre in Shanghai for conferences and research. Harvard President Drew Gilpin Faust said the campaign will help the school meet the world's increasingly complex needs. "We will meet these challenges, and in doing so, we will reaffirm what makes Harvard - and universities in general - such essential and irreplaceable contributors to the pursuit of knowledge and the welfare," Faust said in a press release. The campaign quietly began two years ago. Harvard says it has already raised $US2.8 billion ($A2.98 billion) in gifts and pledges, some of which has already been used. The school aims to reach its $US6.5 billion goal by 2018. If it … Continue reading →

Stem Cell Research Project - Diabetes Cure Participants Scenario By: Manasvi … Continue reading →

Amy Norton HealthDay Reporter Posted: Wednesday, September 18, 2013, 2:00 PM WEDNESDAY, Sept. 18 (HealthDay News) -- Scientists have figured out a way to more readily turn adult skin cells into primitive stem cells that could potentially be used to treat a variety of chronic diseases. In a study published Sept. 18 in Nature, Israeli researchers reported that they identified the key molecule that stops adult cells from transforming into so-called induced pluripotent stem (iPS) cells. Those stem cells are similar to the primitive cells found in embryos, and have the potential to generate any type of body tissue, scientists believe. Ultimately, the hope is to use iPS cells to treat damaged tissue in a range of chronic ills -- from heart disease and diabetes, to arthritis, and spinal cord injuries and Alzheimer's disease. That's still some years away, according to the experts, but the new findings are a step forward. "We've already known how to create these cells, but it's an inefficient process," said Konrad Hochedlinger, a stem cell researcher at Massachusetts General Hospital in Boston who was not involved in the study. Right now, it could take weeks to months to coax human skin cells to transform into … Continue reading →

SAN ANTONIO, Texas, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Genetics Policy Institute (GPI), the producer of the annual World Stem Cell Summit, is announcing tonight at BioMed SA's 8th Annual Julio Palmaz Award Dinner that the 2014 World Stem Cell Summit is scheduled for December 3-5, 2014 at the San Antonio Marriott Rivercenter in San Antonio, Texas. The World Stem Cell Summit is the largest interdisciplinary stem cell meeting, featuring more than 170 prominent scientists, business leaders, regulators, policy-makers, economic development officers, patient advocates and experts in law and ethics, presenting the latest scientific discoveries, business models, legal and regulatory solutions and best practices. The event is expected to attract more than 1,500 attendees from 40 nations. Among the regional institutions supporting the Summit along with the City of San Antonio are BioMed SA, the Texas Research and Technology Foundation, the Texas Biomedical Research Institute, the U.S. Army Institute of Surgical Research, the University of Texas Health Science Center San Antonio and its Barshop Institute for Longevity and Aging Studies, the University of Texas at San Antonio and BioBridge Global. GPI Executive Director Bernard Siegel, founder and co-chair of the Summit said, "We are proud to select San Antonio as … Continue reading →

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 44 minutes ago Left column: This is the previous method for creating induced pluripotent stem cells (iPSCs); right column: These are iPSCs produced with the new method developed by Dr. Hanna. Top: Skin cells (red); center: iPSCs from skin cells (green); bottom: superimposed top and center images. Skin cells that have been reprogrammed into iPSCs appear light yellow. Only a small percentage of the cells on the left have been reprogrammed, in contrast with the high success rate seen with the new method on the right. Credit: Weizmann Institute of Science Weizmann Institute scientists show that removing one protein from adult cells enables them to efficiently turn back the clock to a stem-cell-like state. Embryonic stem cells have the enormous potential to treat and cure many medical problems. That is why the discovery that induced embryonic-like stem cells can be created from skin cells (iPS cells) was rewarded with a Nobel Prize in 2012. But the process has remained frustratingly slow and inefficient, and the resulting stem cells are not yet ready for … Continue reading →

Cancer patients or those suffering from Parkinson's disease may not have to wait for donors in future following a "huge leap" forward in stem cell production, scientists have said. Researchers have simplified and improved the laborious three-week process so that it can now be completed within days and with 100% efficiency. This means doctors could eventually treat patients much more quickly using their own cells rather than performing a risky transplant. Jacob Hanna, one of the team behind the discovery, said the procedure would remove the possibility of a transplant patient's body rejecting an organ. "We now know how to control a cell's fate and really understand exactly how to make a stem cell from a skin cell, safely and robustly," he said. "A major goal in the future, the great promise of our research, is that a patient in need of a liver transplant, for example, could go to a clinic and have a biopsy taken. Doctors could then, very quickly and efficiently, make stem cells. "They would then be able to give a patient back the liver cells he needs from his own stem cells and there would be no need to look for donors." Dr Hanna, assistant … Continue reading →